Stada-Arzneimittel AG (SAZ.DE)
-XETRA 34.13 
0.44(1.29%) 11:35AM EDT
| Prev Close: | 33.70 |
|---|
| Open: | 33.70 |
|---|
| Bid: | 34.04 |
|---|
| Ask: | 34.04 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 33.51 - 34.42 |
|---|
| 52wk Range: | 21.10 - 34.42 |
|---|
| Volume: | 425,541 |
|---|
| Avg Vol (3m): | 349,406 |
|---|
| Market Cap: | 2.02B |
|---|
| P/E (ttm): | 20.21 |
|---|
| EPS (ttm): | 1.69 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in EUR.
Headlines
- Stada Arzneimittel AG Earnings Call scheduled for 8:00 am ET todayCCBN(Tue, May 7)
- Q1 2013 Stada Arzneimittel AG Earnings Release - Time Not SuppliedCCBN(Tue, May 7)
- Stada Gains Most in 18 Months as Sales Surpass Estimatesat Bloomberg(Tue, May 7)
- Stada Q1 core earnings rise on Russia growth, Serbia recoveryat Reuters(Tue, May 7)
- Full Year 2012 Stada Arzneimittel AG Earnings Release - Time Not SuppliedCCBN(Thu, Mar 21)
- Full Year 2012 Stada Arzneimittel AG Earnings Presentation Call scheduled for 6:30 am ET todayCCBN(Thu, Mar 21)
- BRIEF-Stada AG 2012 net profit 86.5 mln eur vs 22 mln in 2011at Reuters(Thu, Mar 21)
- German stocks - Factors to watch on March 21at Reuters(Thu, Mar 21)
- Stada Rises as Company Confirms 2014 Forecast: Frankfurt Moverat Bloomberg(Thu, Feb 28)
- Stada 2012 core profit up 45 pct, less than expectedat Reuters(Thu, Feb 28)
- Stada Says Strength of Russian Unit May Attract Bidsat Bloomberg(Fri, Jan 11)
- Sun Is Open to Deals in Europe to Boost Scope, Makov Saysat Bloomberg(Wed, Jan 2)
- Galderma Agrees to Buy Spirig to Gain Skin-Care Treatmentsat Bloomberg(Wed, Dec 12)
- Serbia Agrees With Drugmakers, Wholesalers to Settle Debtat Bloomberg(Tue, Nov 6)
- Sun Pharmaceuticals of India Said to Eye Germany’s Stadaat Bloomberg(Fri, Aug 3)
Reports
- No Reports available for SAZ.DE at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.07 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide.
View More